Patent intelligence · US
US 12091661
Organic compositions to treat HSF1-related diseases
Organic compositions to treat HSF1-related diseases
Patent details — US 12091661
- Jurisdiction
- US
- Status
- granted
- Grant date
- Sep 17, 2024
- Expiration
- Sep 12, 2044
- Applicant
- Arrowhead Pharmaceuticals, Inc.
- Claims
- 20
- CPC classes
- A61K, A61K31/713, A61K45/06, A61P
Quick answer
US 12091661 (Organic compositions to treat HSF1-related diseases) is held by Arrowhead Pharmaceuticals, Inc.. Status: granted. Granted Sep 17, 2024. Expires Sep 12, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Arrowhead Pharmaceuticals, Inc.
- Grant date
- Expiration
- Claims
- 20
- CPC classes
- A61K, A61K31/713, A61K45/06, A61P, A61P19/02, A61P29/00
More from Arrowhead Pharmaceuticals, Inc.
Related pharmaceutical patents in our USPTO index.
-
US 12378558
RNAi agents for inhibiting expression of complement factor B (CFB), pharmaceutical compositions thereof, and methods of use
granted -
US 12365897
RNAi agents for inhibiting expression of mucin 5AC (MUC5AC), compositions thereof, and methods of use
granted -
US 12365899
RNAi agents and compositions for inhibiting expression of apolipoprotein C-III (APOC3)
granted -
US 12221610
RNAi agents for inhibiting expression of HIF-2 alpha (EPAS1), compositions thereof, and methods of use
granted -
US 12188017
Compositions and methods for inhibiting gene expression of alpha-1 antitrypsin
granted -
US 12173086
Alpha-v beta-6 integrin ligands and uses thereof
granted -
US 12116573
Targeting ligands for therapeutic compounds
granted -
US 12110492
RNAi agents for inhibiting expression of complement component C3 (C3), pharmaceutical compositions thereof, and methods of use
granted
Frequently asked questions
What is US patent 12091661?
US 12091661 (Organic compositions to treat HSF1-related diseases) is held by Arrowhead Pharmaceuticals, Inc.. Status: granted. Granted Sep 17, 2024. Expires Sep 12, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 12091661?
Arrowhead Pharmaceuticals, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 126 pharmaceutical patents for this assignee.
When does US 12091661 expire?
Our index shows an expiration date of Sep 12, 2044 (18 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.